AbbVie Advances ABBV-8736 With New Trial Comparing Injection Routes

Abbvie (ABBV) announced an update on their ongoing clinical study.

AbbVie (ABBV) has started a new Phase 1 trial called “A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration.” The goal is to see how the body absorbs ABBV-8736 with a simple under‑the‑skin shot versus a standard IV infusion and what that could mean for future dosing and convenience.

The study tests ABBV-8736 as a drug given in two ways, through an intravenous (IV) injection and a subcutaneous (SC) injection. The aim is to confirm that the under‑the‑skin option delivers enough of the drug into the bloodstream while staying safe and well tolerated in healthy adults.

This is an interventional Phase 1 study in healthy volunteers with randomized group assignment. It uses a parallel design with no blinding, so everyone knows which route they get, and the main goal is basic science: to map drug levels, safety, and immune response with each injection method.

The trial was first submitted on 10 Feb 2026, signaling a fresh early‑stage asset moving into human testing. The latest update on 20 Feb 2026 shows the study is active and being adjusted in real time as AbbVie refines its plans and disclosures.

For investors, this update reinforces AbbVie’s push to grow its pipeline beyond legacy products and improve delivery of next‑generation drugs. While Phase 1 data rarely moves the stock alone, progress on a potentially easier dosing route can support long‑term value and keeps AbbVie competitive with large peers that are also shifting complex therapies to more convenient injection formats.

The study is currently recruiting and remains active, with further details and ongoing updates available on the ClinicalTrials.gov portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.